Stephen Simpson
Integra LifeSciences
MassDevice.com +3 | The top 3 med-tech stories for July 2, 2013
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Integra LifeSciences recall affects Medtronic’s Infuse kits
St. Jude touts CE Mark for next-gen high-energy ICD | Regulatory Roundup
Medical Device Tax: Ten companies in line for a whack
The medical device tax set to take effect next year as part of the Affordable Care Act will see all medical device companies pay a 2.3% levy on U.S. sales. But the tax is likely to strike some companies a lot harder where it hurts the most: the bottom line.
GE, Masimo ink OEM deal | Wall Street Beat
Is Boston Scientific in line for a private equity takeover? | Wall Street Beat
Billionaire hedge fund manager David Tepper, of Appaloosa Management, bought 7.8 million shares of Boston Scientific stock during the 4th quarter, according to regulatory filings, for a stake with a market value of $41.6 million as of Dec. 31.
SonoSite taps new CFO | Personnel Moves
SonoSite (NSDQ: SONO) said it’s replacing retiring CFO Marcus Smith with Anil Amlani, head of its VisualSonics subsidiary.
Smith’s last day as the ultrasound device maker’s top financial mind is today; he’s slated to stay on at the Bothell, Wash.-based company until Jan. 5, according to a press release.
Smith had been with SonoSite since 2007, according to the release.
Ex-Medicare chief says up to 30% of health spending is waste | MassDevice.com On Call
MASSDEVICE ON CALL — Up to 30 percent of the money spent by the Centers for Medicare & Medicaid Services is wasted, said former agency chief Dr. Donald Berwick.
In an interview given on his last day at the helm, Berwick blamed the high level of waste partly on inefficiencies within the agency.
LeMaitre Vascular CEO: Two new products on tap | Wall Street Beat
George LeMaitre, chairman & CEO of the vascular device firm that bears his name, told analysts on a conference call that LeMaitre Vascular (NSDQ:LMAT) has two new products it expects to launch during the fourth quarter.
The Burlington, Mass.-based company is in the last stages of post-approval trials for the devices – the UnBalloon and an over-the-wire device used to excise heart valves – LeMaitre said during a call to discuss LMAT’s third-quarter numbers.
HeartWare’s Q3 sales rise, losses widen; CFO to step down | Earnings Roundup
HeartWare International (NSDQ:HTWR) posted record revenues of $21.3 million during the third quarter, up 54.4 percent, but saw losses gap wider by a whopping 78 percent.
The Framingham, Mass.-based medical device maker also said CFO David McIntyre is stepping down to move back to Australia to rejoin family.
HeartWare posted a net loss of $14.0 million, or $1.00 per share, for the three months ended Sept. 30. That compares with losses of $7.8 million, or 57 cents per share, on sales of $13.8 million during the same period last year.